Varicella zoster virus encephalitis: a potentially serious complication during treatment with vedolizumab.

Miriam Celada-SendinoLorena Carballo-FolgosoRuth de FranciscoIsabel Pérez-MartínezAndrés Castaño-GarcíaSabino Riestra

Published in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2022)

Vedolizumab is a monoclonal antibody that has demonstrated efficacy and a good safety profile in patients with inflammatory bowel disease. Varicella zoster virus encephalitis is a potentially serious complication not previously described with its use, highlighting the importance of vaccination, as well as early diagnosis and treatment of infections in this type of patients.

Keyphrases

patients with inflammatory bowel disease
monoclonal antibody
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
ulcerative colitis
peritoneal dialysis
patient reported outcomes
patient reported